| Autor: |
Dimitrios Alexopoulos, Vassiliki-Maria Dragona, Charalampos Varlamos, Dionysios Ktenas, Ioannis Lianos, Sotirios Patsilinakos, Dimitrios Sionis, Ioannis Zarifis, Theodora Bampali, Leonidas Poulimenos, Emmanouil Skalidis, Evangelos Pissimisis, Athanasios Trikas, Ioannis Tsiafoutis, Nickolaos Kafkas, Christoforos Olympios, Dimitrios Tziakas, Antonios Ziakas, Vassilis Voudris, Ioannis Kanakakis, Costas Tsioufis, Periklis Davlouros, Despoina-Rafailia Benetou |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Journal of cardiovascular pharmacology. |
| ISSN: |
1533-4023 |
| Popis: |
GReek-AntiPlatElet Atrial Fibrillation (GRAPE-AF) registry is a multicenter, observational, non-interventional study of AF patients undergoing PCI. Primary endpoint included clinically significant bleeding rate at 12 months between different antithrombotic regimens prescribed at discharge; secondary endpoints included major adverse cardiovascular events (MACEs) as well as net adverse clinical events (NACEs).A total of 647 patients were analyzed. The majority (92.9%) were discharged on NOACs with only 7.1% receiving VKA. A little over half of patients (50.4%) received triple antithrombotic therapy (TAT) - mostly (62.9%) for ≤ 1 month - while the rest (49.6%) received dual antithrombotic therapy (DAT). Clinically significant bleeding risk was similar between TAT and DAT (HR = 1.08; 95% CI = 0.66 - 1.78), though among TAT-receiving patients, the risk was lower in those receiving TAT for ≤ 1 month (HR = 0.50; 95% CI = 0.25 - 0.99). Anticoagulant choice (NOAC vs VKA) did not significantly affect bleeding rates (P=0.258). Age, heart failure, leukemia/myelodysplasia and acute coronary syndrome were associated with increased bleeding rates. Risk of MACEs and NACEs was similar between ΤAT and DAT (HR = 1.73; 95% CI = 0.95 - 3.18, P = 0.075 and HR = 1.39; 95% CI = 0.93 - 2.08, P=0.106, respectively).In conclusion, clinically significant bleeding and ischemic rates were similar between DAT and TAT, although TAT1 month was associated with higher bleeding risk. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
